Pathfinder Financial Statements From 2010 to 2025
| PFND Stock | USD 0.0001 0.00 0.00% |
Check Pathfinder Cell financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pathfinder Cell's main balance sheet or income statement drivers, such as , as well as many indicators such as . Pathfinder financial statements analysis is a perfect complement when working with Pathfinder Cell Valuation or Volatility modules.
Pathfinder |
Pathfinder Cell Therapy Company Return On Asset Analysis
Pathfinder Cell's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Pathfinder Cell Return On Asset | -8.89 |
Most of Pathfinder Cell's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pathfinder Cell Therapy is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Pathfinder Cell Therapy has a Return On Asset of -8.8876. This indicator is about the same for the Biotechnology average (which is currently at -8.75) sector and 62.34% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Pathfinder Cell Therapy Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pathfinder Cell's current stock value. Our valuation model uses many indicators to compare Pathfinder Cell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pathfinder Cell competition to find correlations between indicators driving Pathfinder Cell's intrinsic value. More Info.Pathfinder Cell Therapy is rated below average in return on asset category among its peers. It is rated below average in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pathfinder Cell's earnings, one of the primary drivers of an investment's value.About Pathfinder Cell Financial Statements
Pathfinder Cell stakeholders use historical fundamental indicators, such as Pathfinder Cell's revenue or net income, to determine how well the company is positioned to perform in the future. Although Pathfinder Cell investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pathfinder Cell's assets and liabilities are reflected in the revenues and expenses on Pathfinder Cell's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pathfinder Cell Therapy. Please read more on our technical analysis and fundamental analysis pages.
Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts. PATHFINDER CELL operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 1 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Pathfinder Pink Sheet
Pathfinder Cell financial ratios help investors to determine whether Pathfinder Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pathfinder with respect to the benefits of owning Pathfinder Cell security.